Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (NASDAQ:BBNX), filed a Form 4 on November 18, 2026, disclosing transactions in Beta Bionics common stock dated November 16, 2026.

Key Highlights

  • Option exercise: Hopman acquired 775 shares of common stock on November 16, 2026, via exercise of an employee stock option at a price of $5.10 per share.
  • Sale of shares: Hopman disposed of 775 shares of common stock on November 16, 2026, at a price of $16.22 per share.
  • 10b5-1 plan: According to the filing, the sale was made pursuant to a Rule 10b5-1 plan adopted on June 10, 2026.
  • Remaining common stock: Following the transactions, Hopman directly held 54,143 shares of common stock.
  • Remaining options: Hopman retained 20,950 employee stock options with an exercise price of $5.10 and an expiration date of September 13, 2033.
  • Option vesting: The filing states the option shares vest in 48 equal monthly installments measured from September 14, 2023.

Hopman's November 16 Option Exercise and Planned Share Sale at Beta Bionics

Mark Hopman, identified in the filing as Chief Commercial Officer of Beta Bionics, Inc. (NASDAQ:BBNX), reported two transactions in the company's common stock on November 16, 2026. The filing was submitted on November 18, 2026, and was signed by Thomas Sohn as Attorney-in-Fact.

According to the filing, Hopman first exercised an employee stock option, acquiring 775 shares of common stock at an exercise price of $5.10 per share. This brought his directly held common stock to 54,918 shares following that transaction. He then disposed of 775 shares at $16.22 per share, reducing his direct beneficial ownership to 54,143 shares. The filing notes the sale was executed pursuant to a Rule 10b5-1 plan that Hopman adopted on June 10, 2026. The form also indicates the box was checked confirming the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

In Table II, the filing reports that 775 employee stock options with an exercise price of $5.10 and an expiration date of September 13, 2033, were exercised (transaction code M) with a derivative security price of $0.00. The filing states those options vest in 48 equal monthly installments measured from September 14, 2023. After this exercise, Hopman's remaining directly held employee stock options totaled 20,950.

What Was Disclosed

Beta Bionics CCO Mark Hopman filed a Form 4 disclosing a November 16, 2026, option exercise of 775 shares at $5.10 and a same-day sale of 775 shares at $16.22, carried out under a Rule 10b5-1 plan adopted June 10, 2026, leaving him with 54,143 shares and 20,950 options.